Medical Care Technologies Inc. (OTC Pink:MDCE) Previews MDCE Melanoma Scan Beta on Corporate Website

Rhea-AI Summary

Medical Care Technologies (OTC Pink:MDCE) announced a public beta preview of MDCE Melanoma Scan, now available in the applications section of its corporate website. The tool is an early-stage healthcare AI initiative for visual analysis in preventive health awareness and supports MDCE’s broader multi-sector AI growth strategy.

According to the company, the beta has no regulatory clearance and is not intended for diagnosis or treatment. MDCE continues to pursue AI initiatives while using subsidiaries Infinite Auctions and Real Game Used as revenue-generating operations.

News Market Reaction – MDCE

+50.00%

+50.00% Session close to close

In the May 22 session, MDCE gained 50.00%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MDCE Strengthens Its Artificial Intelligence Expansion Strategy With New Healthcare Beta Preview and Multi-Sector Growth Initiatives

MESA, AZ / ACCESS Newswire / May 22, 2026 / Medical Care Technologies Inc. (OTC Pink:MDCE) ("MDCE" or the "Company"), a diversified artificial intelligence-focused technology company, today announced the public beta preview of MDCE Melanoma Scan, now featured in the applications section of the Company's corporate website at https://medicalcaretechnologies.com/#applications.

The beta preview marks Medical Care Technologies' continued expansion into healthcare-focused artificial intelligence applications as the Company advances its broader AI growth strategy across consumer, wellness, enterprise, and medical technology sectors.

MDCE Melanoma Scan represents an early-stage healthcare AI initiative focused on exploring visual analysis applications in preventive health awareness. The beta preview adds to the Company's growing AI roadmap, which includes recently launched consumer AI initiatives and additional enterprise and healthcare-focused concepts currently under development.

"Medical Care Technologies is focused on building scalable AI opportunities across multiple high-growth sectors," said Marshall Perkins III, Chief Executive Officer of Medical Care Technologies Inc. "The preview of MDCE Melanoma Scan reflects our continued expansion into healthcare-oriented AI as we execute on our broader artificial intelligence strategy."

The Company continues evaluating multiple artificial intelligence initiatives while leveraging its wholly owned subsidiaries, Infinite Auctions and Real Game Used, as revenue-generating business operations supporting broader corporate growth.

MDCE Melanoma Scan is currently in beta-stage development, has not received regulatory clearance, and is not intended to diagnose, treat, cure, or prevent any disease or replace professional medical evaluation.

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC Pink:MDCE) is a diversified technology company focused on the development and commercialization of artificial intelligence-powered applications spanning healthcare, wellness, nutrition, lifestyle, and enterprise imaging analysis. The Company also operates wholly owned subsidiaries Infinite Auctions and Real Game Used.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product development, commercialization, strategic expansion, and future business opportunities. Actual results may differ materially due to various risks and uncertainties, including development timelines, capital availability, market conditions, and regulatory considerations. The Company undertakes no obligation to update forward-looking statements except as required by law.

Investor / Media Contact:
Medical Care Technologies Inc.
1910 S Stapley Drive
Suite 221
Mesa, AZ 85204
+1 480-645-0750
info@medicalcaretechnologies.com

X: https://x.com/medicalcaretech
Website: https://medicalcaretechnologies.com/

SOURCE: Medical Care Technologies, Inc.

View the original press release on ACCESS Newswire

FAQ

What is MDCE Melanoma Scan and how does it fit Medical Care Technologies’ (OTC Pink:MDCE) AI strategy?

MDCE Melanoma Scan is an early-stage healthcare AI beta focused on visual analysis for preventive health awareness. According to the company, it supports a broader artificial intelligence strategy spanning consumer, wellness, enterprise, and medical technology sectors as part of a multi-sector AI roadmap.

Is MDCE Melanoma Scan from Medical Care Technologies (MDCE) FDA approved or cleared by regulators?

MDCE Melanoma Scan has not received regulatory clearance and is in beta-stage development. According to the company, it is not intended to diagnose, treat, cure, or prevent any disease, nor to replace professional medical evaluation or clinical decision-making by licensed healthcare providers.

Where can investors and users access the MDCE Melanoma Scan beta preview from Medical Care Technologies (MDCE)?

The MDCE Melanoma Scan beta preview is available in the applications section of Medical Care Technologies’ corporate website. According to the company, users can visit its site and navigate to the applications area to view information about the beta-stage preventive health awareness AI initiative.

How does MDCE Melanoma Scan support Medical Care Technologies’ multi-sector artificial intelligence growth plan?

MDCE Melanoma Scan expands Medical Care Technologies’ presence in healthcare-focused AI through visual analysis for preventive health awareness. According to the company, this beta complements existing consumer AI initiatives and additional enterprise and healthcare concepts that are part of its broader multi-sector AI growth strategy.

What role do Infinite Auctions and Real Game Used play in Medical Care Technologies’ (MDCE) AI expansion?

Infinite Auctions and Real Game Used are wholly owned subsidiaries that generate revenue for Medical Care Technologies. According to the company, these operations support broader corporate growth while MDCE evaluates and develops multiple artificial intelligence initiatives, including healthcare, consumer, wellness, and enterprise-focused AI projects such as MDCE Melanoma Scan.

What limitations has Medical Care Technologies (MDCE) disclosed about the MDCE Melanoma Scan beta?

MDCE Melanoma Scan is a beta-stage healthcare AI tool without regulatory clearance and significant clinical validation. According to the company, it is not meant to diagnose, treat, cure, or prevent disease, and should not replace professional medical evaluation, diagnosis, or treatment from qualified healthcare providers.